EPIGENETIC CANCER THERAPY

EPIGENETIC CANCER THERAPY

Editorial:
ACADEMIC PRESS
Año de edición:
Materia
Genética
ISBN:
978-0-12-800206-3
Páginas:
748
N. de edición:
1
Idioma:
Inglés
Ilustraciones:
50
Disponibilidad:
Disponible en 10 días

Descuento:

-5%

Antes:

112,32 €

Despues:

106,70 €

Features:
- Concisely summarizes the therapeutic implications of recent, large-scale epigenome studies, including the cancer epigenome atlas
- Discusses targeted isoform specific versus pan-specific inhibitors, a rational drug design approach to epigenetics relevant to pharmacoepigenetic clinical applications
- Covers new findings in the interplay between cancer stem cells (CSCs) and drug resistance, demonstrating that epigenetic machinery is a candidate target for the eradication of these CSCs.

Author
Steven Gray, Senior Clinical Scientist & Adjunct Assistant Professor, Thoracic Oncology Research Group, Trinity Centre for Health Sciences, St. James's Hospital, Dublin, Ireland.

Table Of Contents:
1. Introduction
2. DNA Methylation & Hydroxymethylation in Cancer
3. Writers, Readers, and Erasers of Epigenetic Marks
4. MicroRNAs and Cancer
5. Long Noncoding RNAs (lncRNAs) and Cancer
6. Ribosomal RNA Methylation and Cancer
7. Mining the Epigenetic Landscape: Surface Mining or Deep Underground
8. Development of Epigenetic Targeted Therapies in Hematological Malignancies: From Serendipity to Synthetic Lethality
9. Epigenetic Therapy in Lung Cancer and Mesothelioma
10. Breast Cancer Epigenetics
11. Therapeutic Applications of the Prostate Cancer Epigenome
12. Liver Cancer (Hepatocellular Carcinoma)
13. Neuroblastoma
14. The Epigenetics of Medulloblastoma
15. Clinical Significance of Epigenetic Alterations in Glioblastoma
16. Esophageal Cancer
17. Nasopharyngeal Cancer
18. Nutritional Epigenetic Inhibitors in the Field of Cancer: New Avenues for Chemopreventive Approaches
19. Emerging Epigenetic Therapies - Lysine Methyltransferase/PRC Complex Inhibitors
20. Inhibitors of Jumonji C Domain Histone Demethylases
21. Emerging Epigenetic Therapies - Lysine Acetyltransferase Inhibitors
22. Emerging Epigenetic Therapies - Bromodomain Ligands
23. Clinical Trials
24. Genetic Intratumor Heterogeneity
25. Epigenetics Underpinning DNA Damage repair
26. Epigenetics of Cisplatin Resistance
27. Therapeutically Targeting Epigenetic Regulation of Cancer Stem Cells
28. Personalized Therapy - Chemosensitivity Testing
29. Personalized Therapy - Epigenetic Profiling as Predictors of Prognosis and Response